Aspen Pharmacare (APN) investor relations material

Executive summary

• H1 2026 performance was driven by strong Commercial Pharma growth, especially in emerging markets, but offset by a significant decline in Manufacturing due to the loss of an mRNA contract and restructuring costs.

• APAC divestment is progressing, with proceeds expected to eliminate or materially reduce net debt, enhance balance sheet flexibility, and allow for potential share buybacks.

• Free cash flow exceeded expectations, supported by lower CapEx, reduced working capital, and strong operational cash generation.

• Settlement of mRNA Manufacturing contract dispute resulted in EUR25 million proceeds, but absence of prior mRNA contribution led to lower EBITDA year-over-year.

• H1 2026 is considered transitional, with stronger H2 2026 expected.

Financial highlights

• Group revenue declined 4% year-over-year to R21.1 billion, mainly due to Manufacturing segment decline.

• Normalised EBITDA fell 13% to R5.1 billion, with Commercial Pharma offset by Manufacturing losses.

• Normalised headline EPS dropped 21% to 574.8 cents; headline EPS fell 35% to 417.4 cents.

• Free cash flow for the half was just under R2 billion, a significant improvement from negative R0.8 billion last year, with a cash conversion rate of 193%.

• Net debt reduced to R28.6 billion from R31.2 billion in June 2025, with leverage ratio at 3.4x.

Outlook and guidance

• Commercial Pharma expected to deliver mid-single-digit organic CER revenue growth and double-digit CER EBITDA growth for FY 2026.

• Manufacturing EBITDA expected to be in line with prior year, with operational improvements offsetting loss of mRNA contribution.

• Group targets at least double H1 EBITDA in H2 2026, anticipating double-digit CER growth in normalised headline earnings for FY 2026.

• Steriles business targeted to reach positive EBITDA and cash flow by 2027.

• CapEx reduction and stable tax rates to support ongoing free cash flow strength.